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children. Combined therapy of ICS + BD with or without LAs
was observed in 70% of privately insured children compared 
to 44% of social assistance children. Despite apparently better
management in the private group, OS use, indicating a severe
exacerbation, was 16% in the private compared to 12% in the
publicly insured group. While the average annual number of
claims were similar in the private and public groups (7.3 vs. 7.1),
privately insured children had more ICS claims (3.2 vs. 2.9) 
and fewer BD claims (2.9 vs. 3.9). CONCLUSIONS: Privately
insured children appeared to be better managed than social assis-
tance children. Differences in socioeconomic status and formu-
lary listings may explain observed differences. Policies governing
public and private drug plans must ensure adequate access to
necessary medications for children with asthma.
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OBJECTIVE: To describe the asthma-related pharmacotherapy
utilization following a ﬁrst and second morbid event for asthma
among children and adolescents enrolled in Medicaid.
METHODS: Medicaid hospitalization and emergency room
(ER) claims with a primary ICD-9 CM diagnosis code for asthma
dated 2002 were extracted for recipients less than 21 years of
age. The corresponding asthma-related prescription claims also
were extracted. Recipients with at least two morbid events
(deﬁned as two consecutive ER or hospital visits at least 8 days
apart) formed the study cohort. Pharmacotherapy use for each
recipient was analyzed for up to a 30-day period following
his/her ﬁrst and second morbid event. RESULTS: A total of 214
recipients was identiﬁed as the study cohort consisting mainly 
of infants less than 6 years of age (50.0%), males (61.7%), 
and whites (82.2%). The proportion of recipients who ﬁlled a
prescription for a controller medication following the second
event was greater than the proportion following the ﬁrst event
(40.2% versus 34.1%). A greater proportion of recipients used
leukotriene modiﬁers (24.3%) and inhaled corticosteroids
(20.1%) than other controller drug classes following the ﬁrst
event, as well as following the second event (25.7% and 21.0%,
respectively). Following the ﬁrst event, 59.6% of recipients who
used a leukotriene modiﬁer continued using the same medication
after the second event, compared to only 27.9% of recipients
who used inhaled corticosteroids. With respect to demographic
groups, there was a very low proportion of recipients who were
black who used controller pharmacotherapy following the ﬁrst
(14.7%) and second event (23.5%). CONCLUSION: Although
there was an increase in the proportion of recipients who uti-
lized controller pharmacotherapy after a second morbid event,
there was a low use of these medications overall. Among demo-
graphic groups, blacks had the lowest utilization of controller
medications following morbid events.
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OBJECTIVES: To investigate the trend of treatment costs 
for asthmatic outpatients in Taiwan from 1998 to 2002.
METHODS: Claimed database from Bureau of National Health
Insurance of Taiwan’s whole population were used to compute
the total treatment costs and drug related costs on asthmatic out-
patients during the year 1998 to 2002. Claims with ICD-9-CM
code of asthma were obtained and then sorted per person to cal-
culate the sum of treatment costs per person per year and the
ratio of drug costs per total treatment costs. RESULTS: The fol-
lowing present the yearly data from 1998 to 2002: 1) mean drug
costs per person per year: NT$.1286, 1486, 1873, 1940 and
2114; 2) mean of days per person per year: 26, 29, 36, 40 and
43 days; 3) total treatment costs of asthma : NT$. 4.3 billion,
2.9 billion, 2.4 billion, 2.5 billion and 2.7 billion; and 4) the
ratio of drug costs/total costs: 54.92%, 56.48%, 58.15%,
58.52% and 58.84%. CONCLUSIONS: Drug therapy for
patients with asthma play an important role in asthmatic care.
In Taiwan, the study indicated that drug costs per person per
year is growing every year. Future research will investigate the
appropriateness of these drug therapy and posible drug savings
in the future.
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OBJECTIVE: To determine whether asthma knowledge of care-
givers could improve health outcomes in pediatric patients.
METHODS: The study design was a prospective randomized
controlled trial in asthma patients aged less than 12 years-old.
The study was carried out in asthma clinic at Queen Sirikit
National Institute of Child Health, Bangkok, Thailand between
August 2002 and March 2003. Eleven active and 11 control
patients were invited to attend a clinic. At the clinic the phar-
macists conducted interviews and asked all caregivers to answer
a questionnaire containing 18 true-false questions regarding
asthma knowledge. After completing the questionnaire, phar-
macists provided knowledge of asthma regarding treatment and
environmental care to caregivers in the intervention group.
During the study period, patients in both groups continued to
receive the usual care from their physicians. Patients and care-
givers were followed up during the next six months and the same
process was repeated. The outcome measure was the rate of hos-
pitalization in asthma patient between groups. RESULTS: At
baseline there are no signiﬁcant differences in asthma knowledge
between intervention and control group. At the end of study, the
intervention group is generally better at answering the asthma
questions correctly. The number of hospitalization in the inter-
vention group decreases from 31 to 13 (p < 0.05), whereas there
is no statistically signiﬁcant difference in the control group.
CONCLUSIONS: The present work suggests that pharmacist’s
involvement in asthma clinic has increased caregivers’ knowledge
leading to a decrease in the number of hospitalization. However,
further training is required for caregivers to optimize their role
in helping asthma patients. Further work could be carried out to
determine whether the results of this study are reﬂective of the
knowledge in adult patients.
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OBJECTIVES: The purpose of this abstract is to examine the
direct and indirect costs associated with asthma in an employer
population. This work improves on previous studies of employer
populations with asthma by incorporating measures of the indi-
